Drug Trial Radar · NCT07299825
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 20, 2024
Primary completion
Sep 20, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates
Conditions
- Her 2 Positive Breast Cancer
Interventions
A166Drug
intravenous(IV) infusion (Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate(ORR)Time frame: Within 24 months of last patient enrolled
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Provincial Cancer Hospital
Zhenzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.